Cargando…
New strategies for neuro protection in glaucoma
Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in characteristic optic atrophy and corresponding progressive visual field defect. The exact mechanisms underlying glaucomatous neuron loss are not clear. The main risk factor for glaucoma onset and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520966/ https://www.ncbi.nlm.nih.gov/pubmed/36187483 http://dx.doi.org/10.3389/fcell.2022.983195 |
_version_ | 1784799742276927488 |
---|---|
author | Xuejiao, Yang Junwei, Yan |
author_facet | Xuejiao, Yang Junwei, Yan |
author_sort | Xuejiao, Yang |
collection | PubMed |
description | Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in characteristic optic atrophy and corresponding progressive visual field defect. The exact mechanisms underlying glaucomatous neuron loss are not clear. The main risk factor for glaucoma onset and development is high intraocular pressure (IOP), however traditional IOP-lowering therapies are often not sufficient to prevent degeneration of RGCs and the vision loss may progress, indicating the need for complementary neuroprotective therapy. This review summarizes the progress for neuro protection in glaucoma in recent 5 years, including modulation of neuroinflammation, gene and cell therapy, dietary supplementation, and sustained-release system. |
format | Online Article Text |
id | pubmed-9520966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95209662022-09-30 New strategies for neuro protection in glaucoma Xuejiao, Yang Junwei, Yan Front Cell Dev Biol Cell and Developmental Biology Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in characteristic optic atrophy and corresponding progressive visual field defect. The exact mechanisms underlying glaucomatous neuron loss are not clear. The main risk factor for glaucoma onset and development is high intraocular pressure (IOP), however traditional IOP-lowering therapies are often not sufficient to prevent degeneration of RGCs and the vision loss may progress, indicating the need for complementary neuroprotective therapy. This review summarizes the progress for neuro protection in glaucoma in recent 5 years, including modulation of neuroinflammation, gene and cell therapy, dietary supplementation, and sustained-release system. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520966/ /pubmed/36187483 http://dx.doi.org/10.3389/fcell.2022.983195 Text en Copyright © 2022 Xuejiao and Junwei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Xuejiao, Yang Junwei, Yan New strategies for neuro protection in glaucoma |
title | New strategies for neuro protection in glaucoma |
title_full | New strategies for neuro protection in glaucoma |
title_fullStr | New strategies for neuro protection in glaucoma |
title_full_unstemmed | New strategies for neuro protection in glaucoma |
title_short | New strategies for neuro protection in glaucoma |
title_sort | new strategies for neuro protection in glaucoma |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520966/ https://www.ncbi.nlm.nih.gov/pubmed/36187483 http://dx.doi.org/10.3389/fcell.2022.983195 |
work_keys_str_mv | AT xuejiaoyang newstrategiesforneuroprotectioninglaucoma AT junweiyan newstrategiesforneuroprotectioninglaucoma |